EPHB1 (Cytoplasm. Domain)
- Known as:
- EPHB1 (Cytoplasm. Domain)
- Catalog number:
- AP05062PU-N
- Product Quantity:
- 250 µg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- EPHB1 (Cytoplasm. Domain)
Related genes to: EPHB1 (Cytoplasm. Domain)
- Gene:
- EPHB1 NIH gene
- Name:
- EPH receptor B1
- Previous symbol:
- EPHT2
- Synonyms:
- Hek6
- Chromosome:
- 3q22.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-03-23
- Date modifiied:
- 2016-01-15
Related products to: EPHB1 (Cytoplasm. Domain)
*Please allow 3-5 days for delivery time.* In mammals, TIR domain adapters, including Myd88, TIRAP, TICAM-1 (also called TRIF), and TRAM, act in Toll-like receptor (TLR) signaling pathway. The last me*Please allow 3-5 days for delivery time.* RAIDD (RIP-associated ICH-1 homologous protein with a death domain) is an adaptor molecule that mediates the action of cysteine proteases involved in apoptos09C01,Efha1,EF-hand domain-containing family member A1,Rat,Rattus norvegicus,Smhs2100 kDa coactivator,Bos taurus,Bovine,p100 co-activator,SND1,Staphylococcal nuclease domain-containing protein 1100 kDa coactivator,EBNA2 coactivator p100,Homo sapiens,Human,p100 co-activator,SND1,Staphylococcal nuclease domain-containing protein 1,TDRD11,Tudor domain-containing protein 11100 kDa coactivator,Mouse,Mus musculus,p100 co-activator,Snd1,Staphylococcal nuclease domain-containing protein 1100 kDa coactivator,p100 co-activator,p105 coactivator,Rat,Rattus norvegicus,SND p102,Snd1,Staphylococcal nuclease domain-containing protein 1100 kDa protein,Dd5,E3 ubiquitin-protein ligase UBR5,E3 ubiquitin-protein ligase, HECT domain-containing 1,Edd,Edd1,Hyd,Hyperplastic discs protein homolog,Rat,Rattus norvegicus,Ubr5101F6,CYB561D2,Cytochrome b561 domain-containing protein 2,Homo sapiens,Human,LUCA12.2,Putative tumor suppressor protein 101F6101f6,Cyb561d2,Cytochrome b561 domain-containing protein 2,Mouse,Mus musculus,Putative tumor suppressor protein 101F6110 kDa protein,FYVE finger-containing Rab5 effector protein rabenosyn-5,Homo sapiens,Human,Rabenosyn-5,ZFYVE20,Zinc finger FYVE domain-containing protein 20116 kDa U5 small nuclear ribonucleoprotein component,Bos taurus,Bovine,EFTUD2,Elongation factor Tu GTP-binding domain protein 2,SNRP116,U5 snRNP-specific protein, 116 kDa,U5-116 kDa116 kDa U5 small nuclear ribonucleoprotein component,Chicken,EFTUD2,Elongation factor Tu GTP-binding domain protein 2,Gallus gallus,RCJMB04_4m11,SNRP116,U5 snRNP-specific protein, 116 kDa,U5-116 kDa116 kDa U5 small nuclear ribonucleoprotein component,EFTUD2,Elongation factor Tu GTP-binding domain-containing protein 2,Homo sapiens,hSNU114,Human,KIAA0031,SNRP116,SNU114 homolog,U5 snRNP-specific pr116 kDa U5 small nuclear ribonucleoprotein component,Eftud2,Elongation factor Tu GTP-binding domain-containing protein 2,Mouse,Mus musculus,Snrp116,U5 snRNP-specific protein, 116 kDa,U5-116 kDa Related articles to: EPHB1 (Cytoplasm. Domain)
- Indigenous chickens play a critical role in food security and climate resilience in smallholder systems, yet their genomic diversity and adaptive potential remain insufficiently characterised. This study employed low-pass whole-genome sequencing (LP-WGS; 0.2-1.99×) to investigate genomic diversity, population structure, inbreeding and candidate environment-associated genomic variation in 33 chickens from highland, midland, and lowland agroecologies in the Tigray region of northern Ethiopia. After imputation and stringent filtering, 23.4 million high-confidence SNPs were retained, including ~ 17% novel variants, indicating substantial uncharacterised genetic diversity in these populations. SNP density (13.8 ± 8.6 SNPs/kb) was comparable to values reported from high-coverage Ethiopian chicken datasets, demonstrating the suitability of LP-WGS for population genomics in resource-limited settings. Marked differences in genomic diversity were observed among ecotypes: midland chickens showed the highest nucleotide diversity (π = 0.00267), followed by lowland (π = 0.00233), whereas highland chickens showed the lowest diversity (π = 0.00203) and elevated genomic inbreeding (F and F ≈ 0.18). Population structure analyses revealed clear genetic separation among ecotypes. PCA (13.91% variation explained) distinguished lowland chickens along PC1 and separated highland from midland along PC2, while ADMIXTURE and F patterns supported three major ancestral genomic backgrounds. Functional annotation of private missense variants uncovered distinct adaptive signatures reflecting the contrasting agroecological conditions. Highland chickens showed enrichment of candidate genes potentially involved in physiological processes relevant to high-altitude environments, including cold response, angiogenesis, cardiovascular regulation and metabolic homeostasis (eg., PARP1, ACOX2, ITGB3, EDNRB, SOX8, and SOX10). Midland chickens exhibited candidate signals of selection in genes with known roles in innate antiviral immunity, bacterial defence and inflammatory regulation (eg., BAK1, CLSTN1, CYSLTR1, CYSLTR2, CXCR7, GIPR, DSCAM, GDAP1, TLR3, TLR4, TLR7, IFIH1, ADORA1, EPHB1, and TMPRSS2). Lowland chickens displayed candidate variants associated with heat-stress response, DNA damage repair, oxidative balance and cardiovascular support under extreme temperatures (e.g., MLH1, BDKRB1, GPR19, FLT1, CCL18, TGM2, and RAMP3). Overall, the results indicate substantial genomic differentiation among ecotypes and suggest candidate environment-associated genetic divergence across Tigray's diverse agroecological zones. These populations may represent important reservoirs of adaptive genetic variation for climate-resilient poultry breeding, warranting further functional validation and conservation-oriented management. - Source: PubMed
Publication date: 2026/09/02
Gebru GebreslassieBelay GurjaZegeye TsadkanDessie TadelleBirhanie MinisterZenebe MulalemSalim BashirKatrina MorrisHanotte OlivierVallejo-Trujillo Adriana - Diabetic kidney disease (DKD) is characterized by heterogeneous renal histological patterns, among which interstitial fibrosis and tubular atrophy (IFTA) is a key determinant of patient outcomes and treatment response. However, blood biomarkers reflecting IFTA burden remain unestablished. - Source: PubMed
Publication date: 2026/08/21
Han Seung SeokSurapaneni Aditya LSchmidt Insa MYun DonghwanMa XufanMoon Kyung ChulSrivastava AnandPalsson RagnarStillman Isaac EWaikar Sushrut SGrams Morgan ERhee Eugene P - BackgroundDifferential expression of long non-coding RNAs (lncRNAs) in brain, serum, and blood show strong potential to distinguish Alzheimer's disease (AD) from healthy controls.ObjectiveTo explore whether lncRNA signatures delineate AD pathology and map to distinct, multidimensional cognitive domains, enhancing specificity in assessing AD severity and progression.MethodsWe profiled 29,603 lncRNAs transcripts in blood samples from 15 AD patients and 15 healthy controls, alongside comprehensive neuropsychological assessments. Generalized Linear Models and Predictive Power Score analyses, with statistical prioritization, identified lncRNAs associated to AD neuropsychological architecture.ResultsSeveral lncRNAs share strongly associated with cognitive performance and AD severity, mapping to genes involved in key AD-related molecular processes, including synaptic and neurotransmitter regulation (e.g., , , ), protein homeostasis and Aβ pathology (e.g., , , ), mitochondrial function and cellular stress (e.g., , ), neuroinflammation and immune regulation (e.g., , , ), epigenetic and transcriptional control (e.g., , , ), neuronal excitability (e.g., ), and neuroprotection and synaptic plasticity (e.g., ). Novel associations included ferroptosis, DNA stability, microtubule dynamics, and dendritic orientation (e.g., , , , , , , ).ConclusionsWe identify candidate lncRNA signatures that may serve as potential biomarkers and enhance our understanding of the molecular basis of the cognitive architecture in AD, opening new avenues for biomarker identification and targeted therapeutic strategies development. Validation in larger, diverse cohorts is essential to confirm their mechanistic contributions to AD. - Source: PubMed
Publication date: 2026/07/29
Mosquera-Heredia María IVidal Oscar MBarceló ErnestoMorales Luis CSilvera-Redondo CarlosBolívar Daniel AAllegri RicardoArcos-Burgos MauricioGaravito-Galofre PilarVélez Jorge I - Circadian disruption affects multiple aspects of human health, but the genetic architecture of individual susceptibility remains unclear. We examined the genetics of the Circadian Imbalance Index (CII), an additive 0-5 score combining evening chronotype, short/long sleep, high neuroticism, atypical caffeinated coffee intake, and low vitamin D. - Source: PubMed
Publication date: 2026/07/21
Żebrowska MagdalenaWielscher MatthiasZhang JingSaksvik-Lehouillier IngvildDiMilia LeeBurns AngusValliere JesseVincenzi LeonardoRedline SusanOkereke OliviaSaxena RichaRichmond RebeccaRutter Martin KSchernhammer Eva S - The treatment of Alzheimer's disease (AD) is severely hampered by the blood-brain barrier (BBB), which limits the delivery of therapeutic agents like donepezil (DPZ), an acetylcholinesterase inhibitor. While DPZ has multi-faceted benefits, its clinical efficacy is constrained by poor BBB penetration, requiring high doses that lead to significant side effects. To overcome this, we developed a brain-targeted nanotherapeutic utilizing apoferritin (AFn) nanoparticles loaded with DPZ (AFn-DPZ). We demonstrate that this platform, by binding to the EphB1 receptor on the blood-brain barrier, enables transient and reversible opening of the blood-brain barrier, thereby facilitating efficient and targeted drug delivery. Following intravenous administration in an AD mouse model, AFn-DPZ exhibited enhanced brain accumulation and sustained release of DPZ. This targeted delivery inhibited acetylcholinesterase activity, reduced amyloid plaque burden, alleviated neuroinflammation, attenuated oxidative damage, restored mitochondrial function, and upregulated the expression of brain-derived neurotrophic factor (BDNF). Consequently, AFn-DPZ treatment significantly improved cognitive performance compared to free DPZ. Our findings establish EphB1-mediated facilitation of BBB traversal as a promising strategy for enhancing nanotherapeutic delivery to the brain, offering a potent approach to address the complex pathology of AD. - Source: PubMed
Publication date: 2026/07/06
Wen ShilinGao JingjingWang ZhixianMa QiuminXu Xiao-LingChen Jianer